Purple Biotech (PPBT) Cash from Operations (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Cash from Operations of 3121000.0 for Q1 2026, down 57.79% year-over-year from 7393219.16 in Q1 2025, and down 192.5% quarter-over-quarter from 1067000.0 in Q4 2025.
Purple Biotech (PPBT) Cash from Operations (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Cash from Operations for 10 consecutive years, with 3121000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 57.79% year-over-year to 3121000.0; the TTM figure through Mar 2026 stood at 6799000.0 (up 39.63% YoY), while the FY2025 annual figure was 5656000.0, up 60.63% from the prior year.
- Cash from Operations fell to 3121000.0 in Q1 2026 per PPBT's latest filing, from 1067000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1067000.0 in Q3 2025 and bottomed at 6064000.0 in Q1 2023.
- Historically, Cash from Operations has averaged 3517882.35 across 5 years, with a median of 3656000.0 in 2023.
- Annual changes were most pronounced in 2025 — Cash from Operations soared 67.62% — and 2026, when it tumbled 57.79%.
- Purple Biotech's Cash from Operations stood at 4214000.0 in 2022, then decreased by 18.22% to 4982000.0 in 2023, then jumped by 59.57% to 2014000.0 in 2024, then jumped by 47.02% to 1067000.0 in 2025, then sank by 192.5% to 3121000.0 in 2026.
- Business Quant data shows PPBT's Cash from Operations at 3121000.0 in Q1 2026, 1067000.0 in Q4 2025, and 1067000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 728.46 Mn |
| 10 | Purple Biotech | 127.07 | 127.07 | - | -2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.12 Mn |
| Mar 31, 2026 | -3.12 Mn |
| Dec 31, 2025 | -1.07 Mn |
| Dec 31, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.54 Mn |
| Jun 30, 2025 | -1.54 Mn |
| Mar 31, 2025 | -1.98 Mn |
| Mar 31, 2025 | -1.98 Mn |
| Dec 31, 2024 | -2.01 Mn |
| Dec 31, 2024 | -2.01 Mn |
| Sep 30, 2024 | -3.30 Mn |
| Sep 30, 2024 | -3.30 Mn |
| Jun 30, 2024 | -3.98 Mn |
| Jun 30, 2024 | -3.98 Mn |
| Mar 31, 2024 | -5.08 Mn |
| Mar 31, 2024 | -5.08 Mn |
| Dec 31, 2023 | -4.98 Mn |
| Dec 31, 2023 | -4.98 Mn |